Treatment option for sepsis in children in the era of antibiotic resistance

References

• Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis*. Pediatr Crit Care Med 2013;14:686-93
   PubMed Web of Science ®Google Scholar
• Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003;167:695-701
   PubMed Web of Science ®Google Scholar
• Folgori L, Livadiotti S, Carletti M, et al. Epidemiology and clinical outcomes of multidrug-resistant gram-negative bloodstream infections in a European tertiary pediatric hospital during a 12-month period. Pediatr Infect Dis J 2014. [Epub ahead of print]
   Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43(Suppl 2):S49-56
   PubMed Web of Science ®Google Scholar
• Miriagou V, Tzelepi E, Daikos GL, et al. Panresistance in VIM-1-producing Klebsiella pneumoniae. J Antimicrob Chemother 2005;55:810-11
   PubMedGoogle Scholar
• Lepape A, Monnet DL. Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria, 2009. Euro Surveill 2009;14
   PubMedGoogle Scholar
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-36
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008;13
   PubMedGoogle Scholar
• Zaidi AK, Thaver D, Ali SA, Khan TA. Pathogens associated with sepsis in newborns and young infants in developing countries. Pediatr Infect Dis J 2009;28:S10-18
   PubMed Web of Science ®Google Scholar
• Blomberg B, Manji KP, Urassa WK, et al. Antimicrobial resistance predicts death in Tanzanian children with bloodstream infections: a prospective cohort study. BMC Infect Dis 2007;7:43
   PubMed Web of Science ®Google Scholar
• Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Updat 2011;14:118-24
   PubMed Web of Science ®Google Scholar
• Garazzino S, Lutsar I, Bertaina C, et al. New antibiotics for paediatric use: a review of a decade of regulatory trials submitted to the European Medicines Agency from 2000–why aren’t we doing better? Int J Antimicrob Agents 2013;42:99-118
   PubMedGoogle Scholar
• Sharland M, Bielicki J. Variation in antimicrobial resistance for key pathogens causing serious infections in children. ARPEC WP6; 2014
   Google Scholar
• Cardinale F, Cappiello AR, Mastrototaro MF, et al. Community-acquired pneumonia in children. Early Hum Dev 2013;89(Suppl 3)):S49-52
   PubMedGoogle Scholar
• Appelbaum PC, Bhamjee A, Scragg JN, et al. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977;2:995-7
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978;299:735-40
   PubMed Web of Science ®Google Scholar
• Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010;16:402-10
   PubMed Web of Science ®Google Scholar
• Shane AL, Stoll BJ. Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. Am J Perinatol 2013;30:131-41
   PubMed Web of Science ®Google Scholar
• Lutsar I, Chazallon C, Carducci FI, et al. Current management of late onset neonatal bacterial sepsis in five European countries. Eur J Pediatr 2014;173:997-1004
   PubMed Web of Science ®Google Scholar
• Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014;68:321-31
   PubMed Web of Science ®Google Scholar
• David MZ, Daum RS. Update on epidemiology and treatment of MRSA infections in children. Curr Pediatr Rep 2013;1:170-81
   PubMedGoogle Scholar
• ECDC. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC; Europe: 2013
   Google Scholar
• Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children’s hospitals in the United States. Clin Infect Dis 2009;49:65-71
   PubMed Web of Science ®Google Scholar
• Johnson AP, Davies J, Guy R, et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother 2012;67:802-9
   PubMed Web of Science ®Google Scholar
• Recent trends in antimicrobial resistance among Streptococcus pneumoniae and Staphylococcus aureus isolates: the French experience. Euro Surveill 2008;13(46): pii 19035
   PubMedGoogle Scholar
• Staphylococcus aureus resistant to vancomycin–United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7
   PubMedGoogle Scholar
• Gould IM. VRSA-doomsday superbug or damp squib? Lancet Infect Dis 2010;10:816-18
   PubMed Web of Science ®Google Scholar
• Melo-Cristino J, Resina C, Manuel V, et al. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 2013;382:205
   PubMed Web of Science ®Google Scholar
• Butler KM. Enterococcal infection in children. Semin Pediatr Infect Dis 2006;17:128-39
   PubMedGoogle Scholar
• Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686-707
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-66
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther 2008;6:671-83
   PubMed Web of Science ®Google Scholar
• Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009;22:582-610
   PubMed Web of Science ®Google Scholar
• Nasa P, Juneja D, Singh O, et al. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome. Eur J Intern Med 2012;23:192-5
   PubMed Web of Science ®Google Scholar
• Badal RE, Bouchillon SK, Lob SH, et al. Etiology, extended-spectrum beta-lactamase rates and antimicrobial susceptibility of gram-negative bacilli causing intra-abdominal infections in patients in general pediatric and pediatric intensive care units–global data from the Study for Monitoring Antimicrobial Resistance Trends 2008 to 2010. Pediatr Infect Dis J 2013;32:636-40
   PubMedGoogle Scholar
• Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. Expert Rev Anti Infect Ther 2014;12:565-80
   PubMed Web of Science ®Google Scholar
• Mesaros N, Nordmann P, Plesiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007;13:560-78
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008;358:1271-81
   PubMed Web of Science ®Google Scholar
• Singh H, Thangaraj P, Chakrabarti A. Acinetobacter baumannii: a brief account of mechanisms of multidrug resistance and current and future therapeutic management. J Clin Diagn Res 2013;7:2602-5
   PubMedGoogle Scholar
• Poirel L, Lebessi E, Heritier C, et al. Nosocomial spread of OXA-58-positive carbapenem-resistant Acinetobacter baumannii isolates in a paediatric hospital in Greece. Clin Microbiol Infect 2006;12:1138-41
   PubMedGoogle Scholar
• Simmonds A, Munoz J, Aguero-Rosenfeld M, et al. Outbreak of Acinetobacter infection in extremely low birth weight neonates. Pediatr Infect Dis J 2009;28:210-14
   PubMedGoogle Scholar
• McGrath EJ, Chopra T, Abdel-Haq N, et al. An outbreak of carbapenem-resistant Acinetobacter baumannii infection in a neonatal intensive care unit: investigation and control. Infect Control Hosp Epidemiol 2011;32:34-41
   PubMedGoogle Scholar
• de Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med 2005;10:185-94
   PubMed Web of Science ®Google Scholar
• Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 2013;39:2070-82
   PubMed Web of Science ®Google Scholar
• Lutsar I, Metsvaht T. Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis. Curr Opin Infect Dis 2010;23:201-7
   PubMedGoogle Scholar
• Hayashi Y, Lipman J, Udy AA, et al. Beta-lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents 2013;41:162-6
   PubMed Web of Science ®Google Scholar
• Lee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010;68:251-8
   PubMed Web of Science ®Google Scholar
• Ahmed A, Paris MM, Trujillo M, et al. Once-daily gentamicin therapy for experimental Escherichia coli meningitis. Antimicrob Agents Chemother 1997;41:49-53
   PubMedGoogle Scholar
• Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013;36:217-30
   PubMedGoogle Scholar
• Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs 2013;15:93-117
   PubMed Web of Science ®Google Scholar
• Tam VH, Schilling AN, Neshat S, et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:4920-7
   PubMed Web of Science ®Google Scholar
• Felton TW, Goodwin J, O’Connor L, et al. Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013;57:5811-19
   PubMed Web of Science ®Google Scholar
• Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9
   PubMed Web of Science ®Google Scholar
• Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007;45:753-60
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 2011;55:4619-30
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999;43:623-9
   PubMed Web of Science ®Google Scholar
• Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol 2013;48:1047-61
   PubMed Web of Science ®Google Scholar
• DeGrado JR, Cios D, Greenwood BC, et al. Pharmacodynamic target attainment with high-dose extended-interval tobramycin therapy in patients with cystic fibrosis. J Chemother 2014;26:101-4
   PubMed Web of Science ®Google Scholar
• De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991;27(Suppl C):41-7
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43:1549-55
   PubMed Web of Science ®Google Scholar
• Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2011;CD005091
   Google Scholar
• Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004;114:e111-18
   PubMed Web of Science ®Google Scholar
• Zakova M, Pong S, Trope A, et al. Dose derivation of once-daily dosing guidelines for gentamicin in critically ill pediatric patients. Ther Drug Monit 2014;36:288-94
   PubMedGoogle Scholar
• Fjalstad JW, Laukli E, van den Anker JN, Klingenberg C. High-dose gentamicin in newborn infants: is it safe? Eur J Pediatr 2013. [ Epub ahead of print]
   PubMedGoogle Scholar
• Best EJ, Gazarian M, Cohn R, et al. Once-daily gentamicin in infants and children: a prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity. Pediatr Infect Dis J 2011;30:827-32
   PubMed Web of Science ®Google Scholar
• Dupuis LL, Sung L, Taylor T, et al. Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration. Pharmacotherapy 2004;24:564-73
   PubMedGoogle Scholar
• Mahmoudi L, Mohammadpour AH, Ahmadi A, et al. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci 2013;17:285-91
   PubMed Web of Science ®Google Scholar
• Layeux B, Taccone FS, Fagnoul D, et al. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010;54:4939-41
   PubMed Web of Science ®Google Scholar
• van Maarseveen E, van Buul-Gast MC, Abdoellakhan R, et al. Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients. J Antimicrob Chemother 2014;69(9):2581-3
   PubMedGoogle Scholar
• Hanna MH, Segar JL, Teesch LM, et al. Urinary metabolomic markers of aminoglycoside nephrotoxicity in newborn rats. Pediatr Res 2013;73:585-91
   PubMed Web of Science ®Google Scholar
• Ariano RE, Zelenitsky SA, Kassum DA. Aminoglycoside-induced vestibular injury: maintaining a sense of balance. Ann Pharmacother 2008;42:1282-9
   PubMed Web of Science ®Google Scholar
• Dille MF, Konrad-Martin D, Gallun F, et al. Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a large prospective study. J Am Acad Audiol 2010;21:409-17
   PubMed Web of Science ®Google Scholar
• Chen K, Bach A, Shoup A, Winick N. Invited reply to amikacin ototoxicity in children with cancer: the problem is the administration schedule. Pediatr Blood Cancer 2013;61:191
   PubMedGoogle Scholar
• Chen KS, Bach A, Shoup A, Winick NJ. Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides. Pediatr Blood Cancer 2013;60:1772-7
   PubMedGoogle Scholar
• Sherwin CM, Svahn S, Van der Linden A, et al. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 2009;65:705-13
   PubMed Web of Science ®Google Scholar
• Reynolds LF, Mailman TL, McMillan DD. Gentamicin in neonates at risk for sepsis - peak serum concentrations are not necessary. Paediatr Child Health 2012;17:310-12
   PubMed Web of Science ®Google Scholar
• Mouton JW, Ambrose PG, Canton R, et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011;14:107-17
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013;56:236-44
   PubMed Web of Science ®Google Scholar
• Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. Clin Infect Dis 2014. [ Epub ahead of print]
   Google Scholar
• Roberts JA, Paul SK, Akova M, et al.I: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014;58:1072-83
   PubMed Web of Science ®Google Scholar
• Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009;53:379-85
   PubMedGoogle Scholar
• Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005;5:581-9
   PubMed Web of Science ®Google Scholar
• Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009;37:2071-8
   PubMed Web of Science ®Google Scholar
• Tamma PD, Putcha N, Suh YD, et al. Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 2011;11:181
   PubMed Web of Science ®Google Scholar
• Teo J, Liew Y, Lee W, Kwa AL. Prolonged infusion versus intermittent boluses of beta-lactam antibiotics for treatment of acute infections: a meta-analysis. Int J Antimicrob Agents 2014;43:403-11
   PubMed Web of Science ®Google Scholar
• Bauer KA, West JE, O’Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2013;57:2907-12
   PubMed Web of Science ®Google Scholar
• Walker MC, Lam WM, Manasco KB. Continuous and extended infusions of beta-lactam antibiotics in the pediatric population. Ann Pharmacother 2012;46:1537-46
   PubMed Web of Science ®Google Scholar
• Riethmueller J, Junge S, Schroeter TW, et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009;37:418-23
   PubMedGoogle Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228
   PubMed Web of Science ®Google Scholar
• Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 2005;59:54-61
   PubMed Web of Science ®Google Scholar
• Bertels RA, Semmekrot BA, Gerrits GP, Mouton JW. Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusion. Infection 2008;36:415-20
   PubMed Web of Science ®Google Scholar
• Padari H, Metsvaht T, Korgvee LT, et al. Short versus long infusion of meropenem in very-low-birth-weight neonates. Antimicrob Agents Chemother 2012;56:4760-4
   PubMed Web of Science ®Google Scholar
• van den Anker JN, Pokorna P, Kinzig-Schippers M, et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother 2009;53:3871-9
   PubMed Web of Science ®Google Scholar
• Arlicot N, Rochefort GY, Schlecht D, et al. Stability of antibiotics in portable pumps used for bronchial superinfection: guidelines for prescribers. Pediatrics 2007;120:1255-9
   PubMed Web of Science ®Google Scholar
• Prescott WA Jr, Gentile AE, Nagel JL, Pettit RS. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. P T 2011;36:723-63
   PubMedGoogle Scholar
• Sherwin CM, Medlicott NJ, Reith DM, Broadbent RS. Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child 2014;99:590-4
   PubMed Web of Science ®Google Scholar
• Pawlotsky F, Thomas A, Kergueris MF, et al. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Br J Clin Pharmacol 1998;46:163-7
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med 2013;18:28-34
   PubMed Web of Science ®Google Scholar
• Cole TS, Riordan A. Vancomycin dosing in children: what is the question? Arch Dis Child 2013;98:994-7
   PubMedGoogle Scholar
• Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012;67:17-24
   PubMed Web of Science ®Google Scholar
• Plan O, Cambonie G, Barbotte E, et al. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule. Arch Dis Child Fetal Neonatal Ed 2008;93:F418-21
   PubMed Web of Science ®Google Scholar
• Oudin C, Vialet R, Boulamery A, et al. Vancomycin prescription in neonates and young infants: toward a simplified dosage. Arch Dis Child Fetal Neonatal Ed 2011;96:F365-70
   PubMed Web of Science ®Google Scholar
• Zhao W, Lopez E, Biran V, et al. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child 2013;98:449-53
   PubMed Web of Science ®Google Scholar
• Fung L. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients. Ann Pharmacother 2012;46:e26
   PubMed Web of Science ®Google Scholar
• Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Clin Infect Dis 2012;55(Suppl 3):S181-6
   Google Scholar
• Clinical trails. Available from: www.clinicaltials.gov
   Google Scholar
• Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J 2011;30:712-14
   PubMedGoogle Scholar
• Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008;27:330-4
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. Infection 2012;40:367-71
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Watt KM, Hornik CP, et al. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J 2012;31:935-7
   PubMed Web of Science ®Google Scholar
• Morrow BJ, Pillar CM, Deane J, et al. Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagn Microbiol Infect Dis 2013;75:412-16
   PubMed Web of Science ®Google Scholar
• Kresken M, Becker K, Seifert H, et al. Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany. Eur J Clin Microbiol Infect Dis 2011;30:1095-103
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 2013;11:159-77
   PubMed Web of Science ®Google Scholar
• Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012;34:496-507 e491
   PubMed Web of Science ®Google Scholar
• Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834-44
   PubMed Web of Science ®Google Scholar
• Garazzino S, Krzysztofiak A, Esposito S, et al. Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. J Antimicrob Chemother 2011;66:2393-7
   PubMed Web of Science ®Google Scholar
• Simon A, Mullenborn E, Prelog M, et al. Use of linezolid in neonatal and pediatric inpatient facilities–results of a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis 2012;31:1435-42
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of ’old’ polymyxins: what is new? Diagn Microbiol Infect Dis 2012;74:213-23
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94
   PubMed Web of Science ®Google Scholar
• Tamma PD, Newland JG, Pannaraj PS, et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J 2013;32:17-22
   PubMed Web of Science ®Google Scholar
• Tamma PD, Lee CK. Use of colistin in children. Pediatr Infect Dis J 2009;28:534-5
   PubMedGoogle Scholar
• Kapoor K, Jajoo M, Dublish S, et al. Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients. Pediatr Crit Care Med 2013;14:e268-72
   PubMedGoogle Scholar
• Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012;54:1720-6
   PubMed Web of Science ®Google Scholar
• Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2010;29:127-42
   PubMed Web of Science ®Google Scholar
• Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001;18:211-15
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents 2010;35:497-9
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50
   PubMed Web of Science ®Google Scholar
• Kirby WM. Pharmacokinetics of fosfomycin. Chemotherapy 1977;23(Suppl 1):141-51
   PubMedGoogle Scholar
• Joukhadar C, Klein N, Dittrich P, et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003;51:1247-52
   PubMed Web of Science ®Google Scholar
• Matzi V, Lindenmann J, Porubsky C, et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 2010;65:995-8
   PubMed Web of Science ®Google Scholar
• Traunmuller F, Popovic M, Konz KH, et al. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates. Clin Pharmacokinet 2011;50:493-503
   PubMed Web of Science ®Google Scholar
• Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012;25:450-70
   PubMed Web of Science ®Google Scholar
• Brilene T, Soeorg H, Kiis M, et al. In vitro synergy of oxacillin and gentamicin against coagulase-negative staphylococci from blood cultures of neonates with late-onset sepsis. APMIS 2013;121:859-64
   PubMedGoogle Scholar
• Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2012;56:4856-61
   PubMed Web of Science ®Google Scholar
• Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011;66:1047-51
   PubMed Web of Science ®Google Scholar
• Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014;1:CD003344
   PubMed Web of Science ®Google Scholar
• Tamma PD, Turnbull AE, Harris AD, et al. Less is more: combination antibiotic therapy for the treatment of gram-negative bacteremia in pediatric patients. JAMA Pediatr 2013;167:903-10
   PubMed Web of Science ®Google Scholar
• Sick AC, Tschudin-Sutter S, Turnbull AE, et al. Empiric combination therapy for gram-negative bacteremia. Pediatrics 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Lutsar I, Trafojer UM, Heath PT, et al. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials 2011;12:215
   PubMed Web of Science ®Google Scholar
• Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014;69(9):2305-9
   PubMed Web of Science ®Google Scholar
• Multicenter open-label randomized controlled trial (RCT) to compare colistin alone versus colistin plus meropenem. Available from: http://clinicaltrials.gov/show/NCT01732250
   Google Scholar
• Trial for the treatment of extensively drug-resistant gram-negative bacilli. Available from: http://clinicaltrials.gov/show/NCT01597973
   Google Scholar
• Korvick JA, Bryan CS, Farber B, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992;36:2639-44
   PubMed Web of Science ®Google Scholar
• Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010;38:1651-64
   PubMed Web of Science ®Google Scholar
• Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006;CD003344
   Google Scholar
• Graham PL 3rd, Della-Latta P, Wu F, et al. The gastrointestinal tract serves as the reservoir for gram-negative pathogens in very low birth weight infants. Pediatr Infect Dis J 2007;26:1153-6
   PubMedGoogle Scholar
• Parm U, Metsvaht T, Sepp E, et al. Mucosal surveillance cultures in predicting Gram-negative late-onset sepsis in neonatal intensive care units. J Hosp Infect 2011;78:327-32
   Google Scholar
• Smith A, Saiman L, Zhou J, et al. Concordance of gastrointestinal tract colonization and subsequent bloodstream infections with gram-negative bacilli in very low birth weight infants in the neonatal intensive care unit. Pediatr Infect Dis J 2010;29:831-5
   PubMed Web of Science ®Google Scholar
• Das P, Singh AK, Pal T, et al. Colonization of the gut with Gram-negative bacilli, its association with neonatal sepsis and its clinical relevance in a developing country. J Med Microbiol 2011;60:1651-60
   PubMedGoogle Scholar
• Soeorg H, Huik K, Parm U, et al. Genetic relatedness of coagulase-negative Staphylococci from gastrointestinal tract and blood of preterm neonates with late-onset sepsis. Pediatr Infect Dis J 2013;32:389-93
   PubMedGoogle Scholar
• Evans ME, Schaffner W, Federspiel CF, et al. Sensitivity, specificity, and predictive value of body surface cultures in a neonatal intensive care unit. Jama 1988;259:248-52
   PubMed Web of Science ®Google Scholar
• Choi Y, Saha SK, Ahmed AS, et al. Routine skin cultures in predicting sepsis pathogens among hospitalized preterm neonates in Bangladesh. Neonatology 2008;94:123-31
   PubMed Web of Science ®Google Scholar
• Benenson S, Levin PD, Block C, et al. Continuous surveillance to reduce extended-spectrum beta-lactamase Klebsiella pneumoniae colonization in the neonatal intensive care unit. Neonatology 2012;103:155-60
   PubMedGoogle Scholar
• Cohen MJ, Block C, Levin PD, et al. Institutional control measures to curtail the epidemic spread of carbapenem-resistant Klebsiella pneumoniae: a 4-year perspective. Infect Control Hosp Epidemiol 2011;32:673-8
   PubMed Web of Science ®Google Scholar
• Simon A, Tenenbaum T. Surveillance of multidrug-resistant Gram-negative pathogens in high-risk neonates–does it make a difference? Pediatr Infect Dis J 2013;32:407-9
   PubMedGoogle Scholar
• Hsu AJ, Tamma PD. Treatment of multidrug-resistant gram-negative infections in children. Clin Infect Dis 2014;58:1439-48
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Retamar P, et al. Beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167-74
   PubMed Web of Science ®Google Scholar
• Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis 2013;57:781-8
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55
   PubMed Web of Science ®Google Scholar
• European medicines agency. Available from: www.ema.europa.eu
   Google Scholar
• Oleksiewicz MB, Nagy G, Nagy E. Anti-bacterial monoclonal antibodies: back to the future? Arch Biochem Biophys 2012;526:124-31
   PubMed Web of Science ®Google Scholar
• Oviano M, Fernandez B, Fernandez A, et al. Rapid detection of enterobacteriaceae producing extended spectrum beta-lactamases directly from positive blood cultures by matrix-assisted laser-desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Clin Microbiol Infect 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Tangden T, Hickman RA, Forsberg P, et al. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 2014;58:1757-62
   PubMed Web of Science ®Google Scholar
• Krishnappa LG, Marie MA, Al Sheikh YA. Characterization of carbapenem resistance mechanisms in Klebsiella pneumoniae and in vitro synergy of the colistin-meropenem combination. J Chemother 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006;57:573-6
   PubMed Web of Science ®Google Scholar
• Samonis G, Maraki S, Karageorgopoulos DE, et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012;31:695-701
   PubMed Web of Science ®Google Scholar
• Betts JW, Phee LM, Hornsey M, et al. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae. Antimicrob Agents Chemother 2014;58:3541-6
   PubMed Web of Science ®Google Scholar
• Lingscheid T, Tobudic S, Poeppl W, et al. In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates. Pharmacology 2013;91:214-18
   PubMedGoogle Scholar